title: Risk factors for endometrial cancer among women with a BRCA1 or BRCA2 mutation: a case control study.
abstract: BRCA mutation carriers may use tamoxifen for breast cancer prevention or treatment. Hormone replacement therapy is often prescribed after surgical menopause and oral contraceptives are recommended for ovarian cancer prevention. The objective of this study was to assess the impact of these medications and other risk factors on endometrial cancer risk in BRCA carriers. Women with a BRCA1 or BRCA2 mutation were identified from a registry of mutation carriers. Cases were 83 women who had a diagnosis of endometrial cancer. Controls were 1027 matched women who did not develop endometrial cancer and who had an intact uterus. All women completed a baseline questionnaire, which included questions about ages at menarche and menopause, oral contraceptive use, hormone replacement therapy use, hysterectomy, oophorectomy, breast cancer history and tamoxifen use. We estimated the odds ratio associated with each risk factor in a multivariate analysis. No differences were found between cases and controls in terms of age at menarche, BMI, smoking, or oral contraceptive use. In a multivariate analysis, for women taking estrogen-only hormone replacement therapy, the odds ratio was 0.23 (95% CI 0.03-1.78, p = 0.16), and for women taking progesterone-only hormone replacement therapy the odds ratio was 6.91 (95% CI 0.99-98.1, p = 0.05). The adjusted odds ratio for endometrial cancer associated with a history of tamoxifen use was 3.50 (95% CI 1.51-8.10, p = 0.003). The observed increased risk of endometrial cancer associated with progesterone-only therapy merits further study.
authors.affiliation: Familial Breast Cancer Research, Women's College Research Institute, 790 Bay Street, 7th Floor, Toronto, ON, M5G 1N8, Canada.
authors.forename: Yakir
authors.initials: Y
authors.lastname: Segev
authors.forename: Barry
authors.initials: B
authors.lastname: Rosen
authors.forename: Jan
authors.initials: J
authors.lastname: Lubinski
authors.forename: Jacek
authors.initials: J
authors.lastname: Gronwald
authors.forename: Henry T
authors.initials: HT
authors.lastname: Lynch
authors.forename: Pal
authors.initials: P
authors.lastname: Moller
authors.forename: Charmaine
authors.initials: C
authors.lastname: Kim-Sing
authors.forename: Parviz
authors.initials: P
authors.lastname: Ghadirian
authors.forename: Beth
authors.initials: B
authors.lastname: Karlan
authors.forename: Charis
authors.initials: C
authors.lastname: Eng
authors.forename: Dawna
authors.initials: D
authors.lastname: Gilchrist
authors.forename: Susan L
authors.initials: SL
authors.lastname: Neuhausen
authors.forename: Andrea
authors.initials: A
authors.lastname: Eisen
authors.forename: Eitan
authors.initials: E
authors.lastname: Friedman
authors.forename: David
authors.initials: D
authors.lastname: Euhus
authors.forename: Sun
authors.initials: S
authors.lastname: Ping
authors.forename: Steven A
authors.initials: SA
authors.lastname: Narod
mesh_terms: D000328:Adult; D000368:Aged; D019313:BRCA1 Protein / Q000235:genetics*; D024682:BRCA2 Protein / Q000235:genetics*; D016022:Case-Control Studies; D016889:Endometrial Neoplasms / Q000235:genetics* / Q000517:prevention & control; D015914:Estrogen Replacement Therapy / Q000379:methods*; D005260:Female; D020022:Genetic Predisposition to Disease; D006579:Heterozygote; D006801:Humans; D007044:Hysterectomy; D008875:Middle Aged; D009154:Mutation; D016017:Odds Ratio; D010052:Ovariectomy; D012307:Risk Factors; D013629:Tamoxifen / Q000627:therapeutic use
chemical_list: D019313:BRCA1 Protein; C492913:BRCA1 protein, human; D024682:BRCA2 Protein; C551750:BRCA2 protein, human; D013629:Tamoxifen
references.citation: J Clin Oncol. 2013 Jul 10;31(20):2607-18
references.pmid: 23733771
references.citation: J Clin Oncol. 2013 Aug 10;31(23):2942-62
references.pmid: 23835710
references.citation: Gynecol Oncol. 2006 Jan;100(1):83-8
references.pmid: 16137751
references.citation: Dev Biol. 1997 Apr 15;184(2):385-401
references.pmid: 9133444
references.citation: Lancet. 2008 Feb 16;371(9612):569-78
references.pmid: 18280327
references.citation: Int J Cancer. 2004 Feb 10;108(4):613-9
references.pmid: 14696129
references.citation: Cochrane Database Syst Rev. 2009 Apr 15;(2):CD000402
references.pmid: 19370558
references.citation: Cancer Res. 2004 Aug 1;64(15):5051-3
references.pmid: 15289302
references.citation: BMJ. 1989 Jan 21;298(6667):147-51
references.pmid: 2538173
references.citation: Lancet Oncol. 2013 Nov;14(12):1226-32
references.pmid: 24140203
references.citation: Lancet Oncol. 2007 Jan;8(1):26-34
references.pmid: 17196508
references.citation: Obstet Gynecol. 2001 May;97(5 Pt 2):855-66
references.pmid: 11336777
references.citation: Endocr Relat Cancer. 2010 Sep 23;17(4):R263-71
references.pmid: 20870686
references.citation: N Engl J Med. 1998 Nov 26;339(22):1609-18
references.pmid: 9828250
references.citation: J Natl Cancer Inst. 2005 Nov 16;97(22):1652-62
references.pmid: 16288118
references.citation: Eur J Cancer Prev. 2009 Apr;18(2):95-9
references.pmid: 19337055
references.citation: J Steroid Biochem Mol Biol. 1995 Jun;53(1-6):387-93
references.pmid: 7626486
references.citation: J Natl Cancer Inst. 2008 Oct 1;100(19):1361-7
references.pmid: 18812548
references.citation: Br J Cancer. 2010 Sep 28;103(7):933-8
references.pmid: 20877336
references.citation: Oncogene. 2005 Mar 10;24(11):1831-46
references.pmid: 15674350
references.citation: Int J Gynecol Cancer. 2010 Dec;20(9):1531-4
references.pmid: 21119368
references.citation: Nucl Recept Signal. 2006;4:e006
references.pmid: 16741564
references.citation: Endocr Rev. 1999 Jun;20(3):418-34
references.pmid: 10368777
references.citation: Eur J Surg Oncol. 2006 Dec;32(10):1097-100
references.pmid: 16650962
references.citation: Am J Epidemiol. 1996 Jun 15;143(12):1195-202
references.pmid: 8651218
references.citation: Am J Med. 2008 Jun;121(6):501-508.e3
references.pmid: 18501231
references.citation: Gynecol Oncol. 2013 Jul;130(1):127-31
references.pmid: 23562522
references.citation: Am J Obstet Gynecol. 1989 Dec;161(6 Pt 2):1859-64
references.pmid: 2690639
references.citation: Acta Obstet Gynecol Scand. 1997 Apr;76(4):373-7
references.pmid: 9174435
references.citation: Int J Cancer. 2010 Jan 1;126(1):208-16
references.pmid: 19551854
references.citation: Lancet. 2011 Aug 27;378(9793):771-84
references.pmid: 21802721
references.citation: Gynecol Oncol. 2000 Dec;79(3):477-81
references.pmid: 11104623